Brief: AB Science SA Says EMA Confirmed Negative Opinion For Conditional Marketing Authorization Of Masitinib
17/10/2024 18:34
Oct 17 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR
CONDITIONAL
MARKETING AUTHORISATION OF MASITINIB IN ALS
* AB SCIENCE SA - EMA CONFIRMED NEGATIVE OPINION FOR
CONDITIONAL
MARKETING AUTHORIZATION OF MASITINIB IN TREATMENT OF AMYOTROPHIC
LATERAL SCLEROSIS
* AB SCIENCE SA: DECIDED TO NOTIFY HEALTH CANADA IT WILL NOT
PURSUE RECONSIDERATION FOR MASITINIB IN ALS
Source text for Eikon: ID:nGNX7Qm45s
Further company coverage: ABS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease